Majority of Physicians,(1) Alzheimer's Disease (AD) Carers(1) and the General Public(1) in Five European Countries Understand the Need to Detect and Treat AD Early, Yet the Disease Remains Significant

Vienna (ots/PRNewswire) -

- Attitudinal and Behavioural Barriers(1) - Combined with
Inability to Recognize Disease Symptoms(1) - Contribute to Delay in
Diagnosis and Treatment

A new study presented today at a major International medical
meeting reveals that approximately two-thirds of physicians in the
United Kingdom, France, Italy, Spain and Germany agree that
Alzheimer's disease (AD) is under-diagnosed(1) and under-treated,(1)
and explains how physicians, carers and the general population share
responsibility in the issue. Based on these results, the Steering
Committee overseeing the study recommends the development of
programmes to help physicians meet the specific challenges associated
with diagnosing such a devastating disease, and educational tools for
physicians and the general population to help them spot the early
signs of AD.

According to the study, which was presented at the 2009
Alzheimer's Association International Conference on Alzheimer's
Disease (ICAD 2009) and sponsored by Eisai and Pfizer Inc, physicians
who feel AD is under-diagnosed believe this can be explained by:

- Physician uncertainty in discussing the early stages of AD (76
percent)(1)
- Family tendency to ignore (79 percent)(1) or not watch for (90
percent)(1) the early symptoms
- An apathetic 'what's the point?' attitude, as 57 percent of
physicians(1) agreed that there is little to gain from diagnosis, as
there are no effective treatments
- Emotional barriers making it uncomfortable for physicians to deliver
bad news (54 percent)(1)

These beliefs exist despite the fact that 74 percent of
physicians(1) and 63 percent of carers(1) agree that early treatment
delays the progression of disease symptoms in some patients. The
Steering Committee concluded that such attitudes and behaviours
prevalent across Europe may have a negative impact on AD patients'
and carers' quality of life and ability to benefit from timely
diagnosis. Prompt diagnosis has several advantages, including the
opportunity to start treatment, which can delay decline in ability to
perform day-to-day activities,(3) decrease carer burden(4) and
stress,(5) and delay patient admission to long-term care
institutions.(6) Addressing the disease without delay also provides
more time for a person with AD and their family to adjust to the
news, join support organisations and plan for the future, financially
and emotionally.(7)

"Undoubtedly external political and social factors which vary
from country to country, including government resources, cost and
treatment restrictions, take their toll on diagnosis and treatment
rates. However, this study brings to light attitudinal and
behavioural factors within our control that may be just as important
barriers to effective management of this devastating disease, the
most common form of dementia, which is due to rise by approximately
70 percent by the year 2040, affecting 10 million people in Europe,"
said Professor Roy Jones, Clinical Gerontologist and Geriatrician at
The Research Institute for the Care of Older People, Bath, and Study
Steering Committee Chair.

Need for Increased Awareness of Early AD Symptoms - Among
Physicians and the General Public

Additional results of the "Important Perspectives on Alzheimer's
Care & Treatment," or IMPACT study, highlight an agreement that many
people would not be able to recognize the early signs of AD,(1) or be
able to tell the difference between AD and normal ageing.(1) This is
reinforced by the finding that carers waited an average of 10 months
to call a physician after noticing the signs of disease.(1) Across
all respondents, a majority also feel that general practitioners (vs.
specialists) have a difficult time detecting the early stages of
AD.(1) This delay in seeking a physician's advice, and lack of
awareness of the early signs, may place future patients and their
families at a potential disadvantage in securing the benefits of
timely diagnosis and treatment.(7) As the incidence of AD continues
to rise across Europe,(8) "anyone" could be in the position to
identify signs of AD in someone they love in the future.

"Whilst carers and physicians alike know that early treatment
delays the progression of disease symptoms, almost a year goes by
before carers call physicians, who themselves may then be too
inexperienced, uncertain or otherwise emotionally unable to deliver
timely diagnosis and treatment. Detecting the early signs of the
disease is challenging for everyone, but we need to move people away
from fear, denial and hesitation, so that physicians and the general
population - our future carers - can increase their knowledge of AD,
and put that knowledge into action," said Professor Pablo
Martinez-Lage, Neurologist at the Institut Catala de Neurociencies
Aplicades, Barcelona, and member of the IMPACT Study Steering
Committee.

Desire to Know Outweighs Fear of Disease and its Impact on
Families

IMPACT also suggests that the physicians' perception of the
impact of AD on the family may be greater than that of the carers.
Approximately nine out of ten physicians agree that AD has a
devastating effect on a family,(1) but significantly fewer carers (75
percent)(1) feel that way. Further, although the study shows AD
carers are the only respondents to fear AD more than cancer,(1) they
would still want to know as soon as possible if they(1) or a family
member had the disease.(1)

Marc Wortmann, Executive Director of Alzheimer's Disease
International and member of the IMPACT Study Steering Committee,
said, "We have found through IMPACT that fear does not overwhelm the
carer desire to find out about Alzheimer's disease as early as
possible. Perhaps physicians underestimate this desire to know
because of their unique knowledge of the path ahead and 'over
concern' about the impact of a diagnosis. We need to act now to
address the unique obstacles facing physicians, carers and the
general population, and tackle the barriers influencing how people
feel and act when it comes to Alzheimer's disease. How we choose to
react to today's challenges will determine our ability to best
support the rising numbers of tomorrow's patients and carers. Many
health systems in the world are not ready for this challenge."

Notes to Editors:

About Alzheimer's Disease

Alzheimer's disease, a progressive and degenerative brain
disease,(9) is the most common type of dementia.(9) Dementia affects
more than 30 million people worldwide(10) including more than six
million Europeans.(8) Symptoms of AD may include increased
forgetfulness, repeating or asking the same question frequently, and
problems making decisions.(11) These symptoms gradually affect a
person's cognition, behavior and everyday activities, some severe
enough to have an impact on their work, social activities and family
life.(11) While there is no cure for AD, there are treatments to help
slow the progression of the symptoms of the disease.(12)

About the IMPACT Study

The IMPACT study was conducted online within the United Kingdom,
France, Italy, Spain and Germany by IPSOS on behalf of Eisai and
Pfizer Inc, between April 1 and May 1, 2009, among 500 physicians
(including general practitioners and specialists), 250 AD carers, 50
payors and 1,000 members of the general population age 18 and over.
Statistical differences are noted using a 90 percent confidence
interval. A full methodology is available upon request.

About the IMPACT Study Steering Committee

The IMPACT study was developed and implemented with the oversight
of an expert Steering Committee comprised of a variety of leading AD
specialists, including geriatricians, neurologists, epidemiologists,
primary care physicians, old-age psychiatrists and advocacy leaders
from the United Kingdom, France, Italy, Spain and Germany. The
Committee was sponsored by Eisai and Pfizer Inc.

About Eisai

Eisai is a research-based human health care (hhc) company that
discovers, develops and markets products throughout the world. Eisai
focuses its efforts in three therapeutic areas: Integrative
Neuroscience including neuroscience, neurology and psychiatric
medicine; Integrative Oncology including oncotherapy and
supportive-care treatment and Vascular/Immunological Reaction which
includes acute coronary syndrome, atherothrombotic disease, sepsis,
rheumatoid arthritis, psoriasis and Crohn's disease. Through a global
network of research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the
worldwide health care system. Globally, Eisai operates in five key
regions: its home market of Japan, North America, China,
Asia/Oceania/Middle East and Europe and employs more than 11,000
people worldwide.

Pfizer Inc: Working together for a healthier world(TM)

Founded in 1849, Pfizer is the world's premier biopharmaceutical
company taking new approaches to better health. We discover, develop,
manufacture and deliver quality, safe and effective prescription
medicines to treat and help prevent disease for both people and
animals. We also partner with healthcare providers, governments and
local communities around the world to expand access to our medicines
and to provide better quality health care and health system support.
At Pfizer, more than 80,000 colleagues in more than 90 countries work
every day to help people stay happier and healthier longer and to
reduce the human and economic burden of disease worldwide.

(1) Impact Study 2009: Global Alzheimer's Awareness Study. Data on
File Eisai, Pfizer Ltd
(2) Alzheimer Europe. Dementia in Europe Yearbook 2008. Alzheimer Europe.
2008.
(3) Mohs, R.C. et al. A 1-year, placebo-controlled preservation of
function survival study of donepezil in AD patients. Neurology. 2001;
57:481-488.
(4) Wimo, A. et al. An Economic Evaluation of Donepezil in Mild to
Moderate Alzheimer's Disease: Results of a 1-year, Double-Blind,
Randomized Trial. Dementia and Geriatric Cognitive Disorders. 2003;
15:44-54.
(5) Feldman, H. et al. Efficacy of Donepezil on Maintenance of
Activities of Daily Living in Patients with Moderate to Severe
Alzheimer's Disease and the Effect on Caregiver Burden. Journal
American Geriatrics Society. 2003; 51:737-744.
(6) Geldmacher, D. et al. Donepezil Is Associated with Delayed Nursing
Home Placement in Patients with Alzheimer's Disease. Journal
American Geriatrics Society. 2003; 51:937-944.
(7) Alzheimer's Association. Diagnosis. Available at
http://alz.org/alzheimers_disease_diagnosis.asp and
http://alz.org/alzheimers_disease_life_after_diagnosis.asp
(8) Alzheimer Europe. Policy watch Europe Unites Against Alzheimer's
disease. Dementia In Europe: The Alzheimer Europe Magazine. December
2008;2: 2-11.
(9) Alzheimer's Association. 2009 Alzheimer's Disease Facts and Figures.
Available at:
http://www.nadsa.org/publications/documents/2008_Alzheimers_Facts_web.pdf.
Accessed, June 9, 2009.
(10) Wortmann, M. et al. New Estimates of Numbers of People With Dementia
Worldwide. Alzheimer's Disease International Global Perspective.
2008;18: 10-12.
(11) Alzheimer's Association. 10 Signs of Alzheimer's
http://www.alz.org/alzheimers_disease_10_signs_of_alzheimers.asp
(12) Alzheimer's Association. Treatments Available at
http://alz.org/alzheimers_disease_treatments.asp and
http://www.alz.org/alzheimers_disease_standard_prescriptions.asp

ots Originaltext: Eisai; Pfizer Inc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Andrew Day, Eisai, +44-7973-411-419, Andrew_day@eisai.net; or Louise
Clark, Pfizer, +44-845-300-8033, pressofficeUK@pfizer.com; or Vanessa
Leon, Chamberlain, +44-20-7611-8091, Vleon@chamberlainpr.com